{"id":356613,"date":"2026-11-20T09:52:30","date_gmt":"2026-11-20T04:22:30","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=356613"},"modified":"2026-11-20T09:52:30","modified_gmt":"2026-11-20T04:22:30","slug":"aptech-analyst-review-2","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/aptech-analyst-review-2\/","title":{"rendered":"Aptech Analyst Review 2027: Profit Up 42% as Margins Recover, Stock Still Far Below Its High"},"content":{"rendered":"<div style=\"background:#E8F1FF;border-left:5px solid #1565C0;padding:16px 20px;margin:0 0 20px 0;border-radius:6px;\">\n<p><strong>Aptech Stock Snapshot (19 Nov 2026)<\/strong><\/p>\n<ul>\n<li><strong>Current Market Price (CMP):<\/strong> \u20b983.83<\/li>\n<li><strong>52-Week High \/ Low:<\/strong> \u20b9128.48 \/ \u20b969.10<\/li>\n<li><strong>Market Capitalisation:<\/strong> \u20b9486 crore<\/li>\n<li><strong>P\/E Ratio vs Industry P\/E:<\/strong> 17.9 vs 13.8<\/li>\n<li><strong>Latest Quarter (Q2 FY27) Revenue:<\/strong> \u20b9151.59 crore<\/li>\n<li><strong>Latest Quarter (Q2 FY27) Net Profit:<\/strong> \u20b99.19 crore<\/li>\n<\/ul>\n<\/div>\n<div style=\"background:#F0F9FF;border-left:5px solid #2E7D32;padding:16px 20px;margin:0 0 20px 0;\">\n<p><strong>Quick Answer:<\/strong> The <strong>Aptech analyst review 2027<\/strong> finds no named brokerage coverage as of November 2026. Q2 FY27 revenue rose 9.0% to \u20b9151.59 crore, EBITDA rose 37.9% to \u20b916.4 crore and net profit rose 42.3% to \u20b99.19 crore. The stock closed at \u20b983.83 on 19 November 2026, about 35% below its 52-week high and about 18 times trailing earnings, so any <strong>Aptech share price target 2027<\/strong> view depends on whether the margin recovery holds.<\/p>\n<\/div>\n<p>The <strong>Aptech analyst review 2027<\/strong> covers Aptech, a Mumbai-based education company known for its IT training, Arena Animation and MAAC media schools, and assessment services. Readers searching for an <strong>Aptech share price target 2027<\/strong> will not find a named <strong>brokerage<\/strong> figure, so this review relies on results, the business model and valuation.<\/p>\n<p><a href=\"https:\/\/univest.in\/stocks\/aptecht\/aptech-ltd-share-price-today\">Aptech<\/a> closed at \u20b983.83 on 19 November 2026, about 35% below its 52-week high of \u20b9128.48 and about 21% above its low of \u20b969.10. This Aptech analyst review 2027 explains the profit recovery and what shapes the <strong>Aptech stock outlook 2027<\/strong>.<\/p>\n<p><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=aptech-analyst-review\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/aptech-analyst-review-2\/#What_Analysts_Say_in_the_Aptech_Analyst_Review_2027\" title=\"What Analysts Say in the Aptech Analyst Review 2027\">What Analysts Say in the Aptech Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/aptech-analyst-review-2\/#Q2_FY27_Results_in_the_Aptech_Analyst_Review_2027\" title=\"Q2 FY27 Results in the Aptech Analyst Review 2027\">Q2 FY27 Results in the Aptech Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/aptech-analyst-review-2\/#How_Aptech_Makes_Money\" title=\"How Aptech Makes Money\">How Aptech Makes Money<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/aptech-analyst-review-2\/#Growth_Triggers_in_the_Aptech_Analyst_Review_2027\" title=\"Growth Triggers in the Aptech Analyst Review 2027\">Growth Triggers in the Aptech Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/aptech-analyst-review-2\/#Key_Risks_in_the_Aptech_Analyst_Review_2027\" title=\"Key Risks in the Aptech Analyst Review 2027\">Key Risks in the Aptech Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/aptech-analyst-review-2\/#Aptech_Analyst_Review_2027_Stock_at_a_Glance\" title=\"Aptech Analyst Review 2027: Stock at a Glance\">Aptech Analyst Review 2027: Stock at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/aptech-analyst-review-2\/#Shareholding_Trend\" title=\"Shareholding Trend\">Shareholding Trend<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/aptech-analyst-review-2\/#What_to_Watch_After_the_Aptech_Analyst_Review_2027\" title=\"What to Watch After the Aptech Analyst Review 2027\">What to Watch After the Aptech Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/aptech-analyst-review-2\/#Final_Word_on_the_Aptech_Analyst_Review_2027\" title=\"Final Word on the Aptech Analyst Review 2027\">Final Word on the Aptech Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/aptech-analyst-review-2\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/aptech-analyst-review-2\/#What_does_the_Aptech_analyst_review_2027_show\" title=\"What does the Aptech analyst review 2027 show?\">What does the Aptech analyst review 2027 show?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/aptech-analyst-review-2\/#Is_there_an_Aptech_share_price_target_2027_from_brokerages\" title=\"Is there an Aptech share price target 2027 from brokerages?\">Is there an Aptech share price target 2027 from brokerages?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/aptech-analyst-review-2\/#What_does_Aptech_do\" title=\"What does Aptech do?\">What does Aptech do?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/aptech-analyst-review-2\/#Why_did_Aptechs_profit_fall_in_the_March_2026_quarter\" title=\"Why did Aptech&#8217;s profit fall in the March 2026 quarter?\">Why did Aptech&#8217;s profit fall in the March 2026 quarter?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/aptech-analyst-review-2\/#Is_Aptech_stock_fairly_valued_based_on_the_Aptech_analyst_review_2027\" title=\"Is Aptech stock fairly valued based on the Aptech analyst review 2027?\">Is Aptech stock fairly valued based on the Aptech analyst review 2027?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/aptech-analyst-review-2\/#What_risks_does_the_Aptech_analyst_review_2027_highlight\" title=\"What risks does the Aptech analyst review 2027 highlight?\">What risks does the Aptech analyst review 2027 highlight?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/aptech-analyst-review-2\/#What_should_investors_track_after_the_Aptech_analyst_review_2027\" title=\"What should investors track after the Aptech analyst review 2027?\">What should investors track after the Aptech analyst review 2027?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Analysts_Say_in_the_Aptech_Analyst_Review_2027\"><\/span><strong>What Analysts Say in the Aptech Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Brokerage<\/th>\n<th>Rating<\/th>\n<th>Target Price<\/th>\n<th>Date<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>No verified coverage<\/td>\n<td>Not available<\/td>\n<td>Not available<\/td>\n<td>As of November 2026<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>No named <strong>brokerage<\/strong> covers Aptech. Institutional holding has fallen to less than 1%, and the stock has dropped well off its highs, which has reduced research attention.<\/p>\n<p>The company&#8217;s quarterly trends and its debt-free balance sheet are the main reference points. This Aptech analyst review 2027 uses those along with how the stock compares with its industry.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Q2_FY27_Results_in_the_Aptech_Analyst_Review_2027\"><\/span><strong>Q2 FY27 Results in the Aptech Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Q2 FY27<\/th>\n<th>Q2 FY26<\/th>\n<th>Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Revenue<\/td>\n<td>\u20b9151.59 crore<\/td>\n<td>\u20b9139.13 crore<\/td>\n<td>Up 9.0%<\/td>\n<\/tr>\n<tr>\n<td>EBITDA<\/td>\n<td>\u20b916.40 crore<\/td>\n<td>\u20b911.89 crore<\/td>\n<td>Up 37.9%<\/td>\n<\/tr>\n<tr>\n<td>EBITDA margin<\/td>\n<td>About 10.8%<\/td>\n<td>About 8.5%<\/td>\n<td>Up about 230 bps<\/td>\n<\/tr>\n<tr>\n<td>Net profit<\/td>\n<td>\u20b99.19 crore<\/td>\n<td>\u20b96.46 crore<\/td>\n<td>Up 42.3%<\/td>\n<\/tr>\n<tr>\n<td>H1 FY27 net profit<\/td>\n<td>\u20b916.84 crore<\/td>\n<td>Not compared<\/td>\n<td>Improving<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Revenue grew at a single-digit pace, but <strong>EBITDA margin<\/strong> improved by about 230 basis points, so profit grew much faster. The September quarter was also stronger than the June quarter, when revenue was \u20b9137.55 crore and profit \u20b97.65 crore.<\/p>\n<p>The recovery follows a weak March 2026 quarter, when revenue fell to \u20b9114.94 crore and <strong>net profit<\/strong> to \u20b91.78 crore. In this Aptech analyst review 2027, the last two quarters suggest the business has regained its footing.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_Aptech_Makes_Money\"><\/span><strong>How Aptech Makes Money<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Aptech runs most of its training through franchise centres, earning fees and royalties, and also earns from enterprise and testing services.<\/p>\n<ul>\n<li><strong>Retail education:<\/strong> IT, animation, visual effects, gaming, aviation, hospitality and beauty courses through brands such as Arena Animation and MAAC.<\/li>\n<li><strong>Franchise network:<\/strong> centres in India and abroad run by partners who pay royalties.<\/li>\n<li><strong>Enterprise and assessment:<\/strong> online testing and assessment services for institutions and employers.<\/li>\n<li><strong>Corporate training:<\/strong> skills programmes for companies.<\/li>\n<\/ul>\n<p>FY26 revenue rose to \u20b9519.8 crore from \u20b9476.1 crore, and net profit rose to \u20b923.5 crore from \u20b919.1 crore, though it remained below \u20b929 crore in FY24. Those numbers frame this Aptech analyst review 2027, since profit has yet to return to its earlier level.<\/p>\n<p>A franchise model needs little capital, which is why Aptech carries almost no debt. The flip side is that growth depends on partners opening new centres and on student enrolments, which follow job market trends in IT and media. Demand for animation, visual effects and gaming skills has been helped by growth in streaming and digital content.<\/p>\n<p>The assessment business can be lumpy, since large testing contracts come and go, and that partly explains swings such as the weak March quarter. Smaller education companies, like many stocks in broader indices such as the <a href=\"https:\/\/univest.in\/indices\/nifty-smallcap-100\/nifty-smallcap-100-share-price-today\">Nifty Smallcap 100<\/a>, tend to see sharp share price moves when quarterly profit changes direction.<\/p>\n<p>The company&#8217;s <strong>promoter<\/strong> group is linked to the family of the late investor Rakesh Jhunjhunwala, through Rare Equity and Rekha Jhunjhunwala, which gives the stock a well-known shareholder base despite low institutional ownership.<\/p>\n<p>For investors, the key question is whether the second-quarter margin is sustainable. A franchise-led business can expand margins quickly when enrolments rise, because royalty income grows without matching cost increases. The reverse also applies when enrolments slow, which is why the March 2026 quarter was so weak. Two more steady quarters would help confirm that the recovery is durable.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Growth_Triggers_in_the_Aptech_Analyst_Review_2027\"><\/span><strong>Growth Triggers in the Aptech Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Margin recovery:<\/strong> <strong>EBITDA<\/strong> margin up to about 10.8%.<\/li>\n<li><strong>Profit growth:<\/strong> Q2 profit up 42.3%.<\/li>\n<li><strong>Digital content demand:<\/strong> more need for animation and VFX skills.<\/li>\n<li><strong>Asset-light model:<\/strong> franchise growth needs little capital.<\/li>\n<li><strong>Low debt:<\/strong> <strong>debt to equity<\/strong> of about 0.10, relevant to any Aptech share price target 2027 view.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_in_the_Aptech_Analyst_Review_2027\"><\/span><strong>Key Risks in the Aptech Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Slow revenue growth:<\/strong> only 9% in <strong>Q2 FY27<\/strong>.<\/li>\n<li><strong>Lumpy assessment income:<\/strong> large contracts can come and go.<\/li>\n<li><strong>Competition:<\/strong> online platforms offer low-cost courses.<\/li>\n<li><strong>Job market:<\/strong> IT and media hiring affects enrolments.<\/li>\n<li><strong>Institutional exit:<\/strong> DII holding fell from 2.39% to 0.58%, a key point in the Aptech analyst review 2027.<\/li>\n<\/ul>\n<p><strong><a href=\"https:\/\/univest.in\/screeners\">Compare Aptech With Other Education Stocks on the Univest Screener<\/a><\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Aptech_Analyst_Review_2027_Stock_at_a_Glance\"><\/span><strong>Aptech Analyst Review 2027: Stock at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Value<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Share Price (19 Nov 2026)<\/td>\n<td>\u20b983.83<\/td>\n<\/tr>\n<tr>\n<td>52-Week High \/ Low<\/td>\n<td>\u20b9128.48 \/ \u20b969.10<\/td>\n<\/tr>\n<tr>\n<td>Market Capitalisation<\/td>\n<td>About \u20b9486 crore<\/td>\n<\/tr>\n<tr>\n<td>P\/E (TTM)<\/td>\n<td>About 17.9<\/td>\n<\/tr>\n<tr>\n<td>Industry P\/E<\/td>\n<td>About 13.8<\/td>\n<\/tr>\n<tr>\n<td>Price to Book<\/td>\n<td>About 2.03<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity<\/td>\n<td>About 12.7%<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.10<\/td>\n<\/tr>\n<tr>\n<td>FY26 Revenue \/ Net Profit<\/td>\n<td>\u20b9519.8 crore \/ \u20b923.5 crore<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The <strong>P\/E<\/strong> of about 18 is above the industry level of about 14, while return on equity is about 13%. In this Aptech analyst review 2027, the multiple assumes the recent margin improvement continues.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Shareholding_Trend\"><\/span><strong>Shareholding Trend<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Holder<\/th>\n<th>Sep 2025<\/th>\n<th>Sep 2026<\/th>\n<th>Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Promoters<\/td>\n<td>47.35%<\/td>\n<td>47.35%<\/td>\n<td>No change<\/td>\n<\/tr>\n<tr>\n<td>Foreign Investors (FII)<\/td>\n<td>0.40%<\/td>\n<td>0.13%<\/td>\n<td>Down 0.27 points<\/td>\n<\/tr>\n<tr>\n<td>Domestic Institutions (DII)<\/td>\n<td>2.39%<\/td>\n<td>0.58%<\/td>\n<td>Down 1.81 points<\/td>\n<\/tr>\n<tr>\n<td>Public<\/td>\n<td>49.87%<\/td>\n<td>51.94%<\/td>\n<td>Up 2.07 points<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Rare Equity holds 20.38% and Rekha Jhunjhunwala 11.04%, and the <strong>promoter<\/strong> stake did not change. Institutions cut their holdings to below 1% while retail investors bought, a cautious signal in the Aptech analyst review 2027.<\/p>\n<p><strong><a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a><\/strong><\/p>\n<p><strong><a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a><\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_to_Watch_After_the_Aptech_Analyst_Review_2027\"><\/span><strong>What to Watch After the Aptech Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Revenue growth:<\/strong> a return to double-digit growth.<\/li>\n<li><strong>Margins:<\/strong> <strong>EBITDA<\/strong> margin holding above 10%.<\/li>\n<li><strong>Enrolments:<\/strong> demand in animation, VFX and IT courses.<\/li>\n<li><strong>Assessment contracts:<\/strong> new large testing mandates.<\/li>\n<li><strong>Coverage:<\/strong> any research that sets an Aptech share price target 2027.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Final_Word_on_the_Aptech_Analyst_Review_2027\"><\/span><strong>Final Word on the Aptech Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Aptech analyst review 2027<\/strong> shows a clear profit recovery, better margins and an asset-light, nearly debt-free model, balanced against slow revenue growth and falling institutional interest. The stock remains well below its 52-week high.<\/p>\n<p>The <strong>Aptech stock outlook 2027<\/strong> depends on enrolments and margins. Univest does not give a buy or sell call.<\/p>\n<div style=\"background:#FFF5F5;border-left:5px solid #C62828;padding:14px 18px;margin:24px 0;\">\n<p style=\"color:#C62828;\"><strong>Disclaimer:<\/strong> This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div class=\"faq-schema\">\n<h3><span class=\"ez-toc-section\" id=\"What_does_the_Aptech_analyst_review_2027_show\"><\/span><strong>What does the Aptech analyst review 2027 show?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>It shows a profit recovery. Q2 FY27 revenue rose 9.0% to \u20b9151.59 crore, EBITDA rose 37.9% to \u20b916.4 crore and net profit rose 42.3% to \u20b99.19 crore. EBITDA margin improved to about 10.8%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_there_an_Aptech_share_price_target_2027_from_brokerages\"><\/span><strong>Is there an Aptech share price target 2027 from brokerages?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>No named brokerage target exists as of November 2026. The stock closed at \u20b983.83 on 19 November 2026, about 35% below its 52-week high of \u20b9128.48. Results and valuation are the main reference points.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_does_Aptech_do\"><\/span><strong>What does Aptech do?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Aptech runs education and skills training through brands such as Arena Animation and MAAC, mostly via franchise centres. It also offers assessment and testing services and corporate training. The company is based in Mumbai.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_did_Aptechs_profit_fall_in_the_March_2026_quarter\"><\/span><strong>Why did Aptech&#8217;s profit fall in the March 2026 quarter?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Revenue dropped to \u20b9114.94 crore and profit to \u20b91.78 crore in that quarter. Assessment income can be lumpy as large contracts end or shift timing. Profit has since recovered to \u20b97.65 crore in Q1 and \u20b99.19 crore in Q2.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Aptech_stock_fairly_valued_based_on_the_Aptech_analyst_review_2027\"><\/span><strong>Is Aptech stock fairly valued based on the Aptech analyst review 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The stock trades at about 17.9 times earnings, above the industry P\/E of about 13.8. Price to book is about 2.03 and return on equity about 12.7%. The valuation assumes margins keep improving.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_does_the_Aptech_analyst_review_2027_highlight\"><\/span><strong>What risks does the Aptech analyst review 2027 highlight?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The main risks are slow revenue growth, lumpy assessment income and competition from online learning platforms. Enrolments depend on IT and media job markets. Institutions have cut their holdings to below 1%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_should_investors_track_after_the_Aptech_analyst_review_2027\"><\/span><strong>What should investors track after the Aptech analyst review 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Track whether revenue growth returns to double digits and EBITDA margin stays above 10%. Watch enrolment trends and new assessment contracts. Any new research coverage also matters.<\/p>\n<\/div>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What does the Aptech analyst review 2027 show?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"It shows a profit recovery. Q2 FY27 revenue rose 9.0% to \u20b9151.59 crore, EBITDA rose 37.9% to \u20b916.4 crore and net profit rose 42.3% to \u20b99.19 crore. EBITDA margin improved to about 10.8%.\"}},{\"@type\":\"Question\",\"name\":\"Is there an Aptech share price target 2027 from brokerages?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No named brokerage target exists as of November 2026. The stock closed at \u20b983.83 on 19 November 2026, about 35% below its 52-week high of \u20b9128.48. Results and valuation are the main reference points.\"}},{\"@type\":\"Question\",\"name\":\"What does Aptech do?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Aptech runs education and skills training through brands such as Arena Animation and MAAC, mostly via franchise centres. It also offers assessment and testing services and corporate training. The company is based in Mumbai.\"}},{\"@type\":\"Question\",\"name\":\"Why did Aptech's profit fall in the March 2026 quarter?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue dropped to \u20b9114.94 crore and profit to \u20b91.78 crore in that quarter. Assessment income can be lumpy as large contracts end or shift timing. Profit has since recovered to \u20b97.65 crore in Q1 and \u20b99.19 crore in Q2.\"}},{\"@type\":\"Question\",\"name\":\"Is Aptech stock fairly valued based on the Aptech analyst review 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The stock trades at about 17.9 times earnings, above the industry P\/E of about 13.8. Price to book is about 2.03 and return on equity about 12.7%. The valuation assumes margins keep improving.\"}},{\"@type\":\"Question\",\"name\":\"What risks does the Aptech analyst review 2027 highlight?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The main risks are slow revenue growth, lumpy assessment income and competition from online learning platforms. Enrolments depend on IT and media job markets. Institutions have cut their holdings to below 1%.\"}},{\"@type\":\"Question\",\"name\":\"What should investors track after the Aptech analyst review 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Track whether revenue growth returns to double digits and EBITDA margin stays above 10%. Watch enrolment trends and new assessment contracts. Any new research coverage also matters.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Aptech grew Q2 FY27 revenue 9% to \u20b9151.59 crore and profit 42% to \u20b99.19 crore as EBITDA margin improved. With no brokerage coverage, we review the skills training and animation education business, the franchise model, valuation and the risks for 2027.<\/p>\n","protected":false},"author":34,"featured_media":356612,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[24444,4341,760,26646],"class_list":["post-356613","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-24444","tag-analyst-review","tag-aptech","tag-education-and-skill-training"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["356612"],"rank_math_title":["Aptech Share Price Target 2027: Stock Review"],"rank_math_description":["Aptech analyst review 2027: Q2 FY27 revenue up 9% to \u20b9152 crore, profit up 42% to \u20b99.2 crore, margin recovery, P\/E near 18, low debt, franchise model risks."],"rank_math_focus_keyword":["Aptech analyst review 2027"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/aptech-analyst-review-2027-profit-up-42-as-margins-recover-stock-still-far-below-1.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/356613","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=356613"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/356613\/revisions"}],"predecessor-version":[{"id":356614,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/356613\/revisions\/356614"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/356612"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=356613"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=356613"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=356613"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}